Clinicobiological and radiological characteristics of patients with rhupus
| n=15 | ||
| Age (years), median (range) | 52 (20–79) | |
| Sex (female/male) | 14/1 | |
| Age at onset of disease (years), median (range) | 36 (11–64) | |
| Onset disease, n (%) | RA | 6 (40%) |
| SLE | 7 (47%) | |
| Rhupus | 2 (13%) | |
| Interval between first symptom and rhupus diagnosis (years), median | 3 (0–29) | |
| SLE criteria | ||
| 1997 ACR criteria, median (range) | 5 (4–6) | |
| Malar rash, n (%) | 8 (53%) | |
| Discoid lupus, n (%) | 2 (13%) | |
| Photosensibility, n (%) | 14 (93%) | |
| Arthritis, n (%) | 15 (100%) | |
| Pericarditis or pleuritis, n (%) | 2 (13%) | |
| Renal, n (%) | 1 (7%) | |
| Neurological disorder, n (%) | 0 | |
| Haematological, n (%) | 13 (87%) | |
| RA criteria | ||
| ACR criteria, median (range) | 6 (4–7) | |
| Morning stiffness (>60 min), n (%) | 15 (100%) | |
| Arthritis >3 joints, n (%) | 15 (100%) | |
| Arthritis of hands, n (%) | 15 (100%) | |
| Symmetrical arthritis, n (%) | 15 (100%) | |
| Rheumatoid nodules, n (%) | 6 (40%) | |
| RF, n (%) Median (range),* (IU/mL) | 10 (67%) 57.5 (17–244) | |
| X-ray changes (erosions), n (%) | 13 (87%) | |
| Antibodies | ||
| Anti-CCP, n (%) Median (range),* (IU/mL) | 9 (60%) 540 (167–1240) | |
| Positive ANA, n (%) | 15 (100%) | |
| Anti-dsDNA, n (%) Median (range),* (IU/mL) | 10 (67%) 99.5 (51–289) | |
| Anti-Ro/SSA, n (%) | 3 (20%) | |
| Anti-La/SSB, n (%) | 1 (7%) | |
| Anti-Sm, n (%) | 1 (7%) | |
| Anti-RNP, n (%) | 2 (13%) | |
*Median rate and range are calculated for patients with detectable autoantibodies.
ACR, American College of Rheumatology; ANA, antinuclear antibodies; anti-dsDNA, anti-double stranded DNA antibodies; anti-RNP, antiribonucleoprotein antibodies; CCP, cyclic citrullinated peptides; n, number of patients; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; Sm, anti-Smith; SS, Sjögren’s syndrome.